Two different substrates have been used to assess the in vitro pro-cessing activity of SpsB: a a native preprotein substrate immunodominant staphylococcal antigen A and b an intramolecul
Trang 1Enzymatic investigation of the Staphylococcus aureus
type I signal peptidase SpsB – implications for the search for novel antibiotics
Smitha Rao C.V.1, Katrijn Bockstael2, Sangeeta Nath3, Yves Engelborghs3, Jozef Anne´1
and Nick Geukens1,*
1 Laboratory of Bacteriology, Katholieke Universiteit Leuven, Belgium
2 Laboratory for Medicinal Chemistry, Katholieke Universiteit Leuven, Belgium
3 Laboratory of Biomolecular Dynamics, Katholieke Universiteit Leuven, Belgium
Staphylococcus aureus is a frequent commensal of the
human skin and nose, but is also responsible for a wide
array of infections, ranging from minor skin infection to
life-threatening conditions such as endocarditis and
haemolytic pneumonia [1] This Gram-positive
bacte-rium is the most common cause of nosocomial
infec-tions S aureus infections are becoming increasingly
difficult to treat because the bacterium has evolved into
a highly successful pathogen when it comes to antibiotic resistance [2] The emergence and spread of strains such
as methicillin-resistant S aureus, vancomycin-interme-diate S aureus and vancomycin-resistant S aureus has become a major concern New drugs are being devel-oped and launched in the market, but most currently
Keywords
arylomycin; IsaA; signal peptidase; SpsB;
Staphylococcus aureus
Correspondence
J Anne´, Laboratory of Bacteriology, Rega
Institute for Medical Research, Katholieke
Universiteit Leuven, Minderbroedersstraat
10, 3000 Leuven, Belgium
Fax: +32 16 337 340
Tel: +32 16 337 371
E-mail: jozef.anne@rega.kuleuven.be
Website: http://www.kuleuven.be/
bacteriology/
*Present address
PharmAbs, Katholieke Universiteit Leuven
Antibody Center, Belgium
(Received 11 July 2008, revised 10 March
2009, accepted 3 April 2009)
doi:10.1111/j.1742-4658.2009.07037.x
Staphylococcus aureus has one essential type I signal peptidase (SPase), SpsB, which has emerged as a potential target in the search for antibiotics with a new mode of action In this framework, the biochemical properties
of SpsB are described and compared with other previously characterized SPases Two different substrates have been used to assess the in vitro pro-cessing activity of SpsB: (a) a native preprotein substrate immunodominant staphylococcal antigen A and (b) an intramolecularly quenched fluorogenic synthetic peptide based on the sequence of the SceD preprotein of Staphy-lococcus epidermidisfor fluorescence resonance energy transfer-based analy-sis Activity testing at different pH showed that the enzyme has an optimum pH of approximately 8 The pH-rate profile revealed apparent
pKa values of 6.6 and 8.7 Similar to the other SPases, SpsB undergoes self-cleavage and, although the catalytic serine is retained in the self-cleav-age product, a very low residual enzymatic activity remained In contrast,
a truncated derivative of SpsB, which was nine amino acids longer at the N-terminus compared to the self-cleavage product, retained activity The specificity constants (kcat⁄ Km) of the full-length and the truncated deriva-tive were 1.85 ± 0.13· 103m)1Æs)1and 59.4 ± 6.4 m)1Æs)1, respectively, as determined using the fluorogenic synthetic peptide substrate These obser-vations highlight the importance of the amino acids in the transmembrane segment and also those preceding the catalytic serine in the sequence of SpsB Interestingly, we also found that the activity of the truncated SpsB increased in the presence of a non-ionic detergent
Abbreviations
CBB, Coomassie brilliant blue; FRET, fluoresence resonance energy transfer; pre-IsaA, immunodominant staphylococcal antigen A precursor; sc-SpsB, self-cleavage product of SpsB; SPase, signal peptidase; tr-SpsB, N-terminally truncated SpsB derivative.
Trang 2developed antimicrobials are derivatives of well-known
and extensively used compound classes [3] and,
there-fore, the chances that the bacterium would develop
cross-resistance to these drugs are quite high However,
in the search for novel classes of antibiotics for
combat-ing this pathogen, new drug targets [4,5] have been in
focus in recent years
Proteins that are destined for transmembrane
trans-port are produced in the cell as preproteins with a
sig-nal peptide that is recognized and cleaved off by sigsig-nal
peptidases (SPases) [6,7] Bacterial type I SPases are
membrane-bound endopeptidases that remove the
sig-nal peptide from proteins on translocation across the
cytoplasmic membrane [8] SPases are unique serine
proteases, and differ from the classical serine proteases
in that they act using a serine⁄ lysine catalytic dyad
mechanism [9–11] Both Gram-positive and
Gram-neg-ative bacterial SPases have regions of high sequence
similarity, which are referred to as boxes A to E [6],
although they differ in certain aspects, including size,
the number of transmembrane segments and substrate
specificity [12] SPases have already been proposed as
antibiotic targets because of their essentiality, the
eas-ier accessibility of the catalytic domain for potential
inhibitors as a result of being located on the outer side
of the cytoplasmic membrane, and the different
cata-lytic mechanism employed compared to that used by
eukaryotic SPases [8] LepB, the SPase of Escherichia
coli, is the most extensively studied SPase The crystal
structure of the soluble form of this enzyme has been
determined [13–15] and NMR data are also available
for the full-length enzyme [16] and the soluble
deriva-tive [17] Among the Gram-posideriva-tive bacteria,
func-tional analysis and biochemical characterization of
type I SPases have been described for Bacillus subtilis
[18], Bacillus amyloliquefaciens [19], Streptomyces
lividans [20] and Streptococcus pneumoniae [21] For
S aureus, two genes, designated spsA and spsB, were
identified encoding homologues of SPase of which only
the latter was shown to be essential [22] SpsB also has
been functionally expressed in E coli and was
demon-strated to process E coli preproteins in vivo [22] It
was predicted that SpsA is an inactive SPase
homo-logue Furthermore, SpsB, but not SpsA, was shown
to be responsible for the removal of the N-terminal
leader of AgrD, in vitro, which also suggested a role
for type I SPases in quorum sensing [23]
In the present study, we report the biochemical
char-acteristics of SpsB and describe two different in vitro
assays for the enzyme: one with its native substrate
immunodominant staphylococcal antigen A precursor
(pre-IsaA) and the other with a fluorogenic synthetic
peptide, SceD In addition, a nonmembrane-bound,
truncated SpsB (tr-SpsB) was designed to determine the effect of removal of the transmembrane segment of SpsB The specific activities of the full-length and the truncated SpsB were compared using the fluoresence resonance energy transfer (FRET)-based assay involv-ing the SceD peptide
Results and discussion
Expression and purification of the full-length SpsB and preprotein IsaA
The gene encoding SpsB was amplified by PCR using primers that were also designed to bring about two modifications: the incorporation of NdeI and EcoRI restriction sites (at the 5¢ and 3¢ ends, respectively) and
a hexa-histidine-encoding sequence for obtaining a His-tag at the N-terminus of the produced protein to facilitate purification The fragments were cloned after the T7 promoter in pET-3a plasmid The proteins expressed in E coli BL21(DE3)pLysS were purified (see Experimental procedures) and analyzed by SDS⁄ PAGE The purification of the full-length SpsB normally yielded samples of sufficient purity (> 95%) and concentration (30–40 lm) (see Supporting infor-mation, Fig S1A)
The gene encoding pre-IsaA was amplified by PCR using oligonucleotides that were also designed to incor-porate NcoI and EcoRI restriction sites and sequences encoding a hexa-histidine tag and a c-Myc tag to appear at N- and C-terminal ends of the expressed protein, respectively The c-Myc tag was included to facilitate immunodetection of the protein The gene was cloned in pET-23d and expressed in E coli
MW = 26.2 kDa, including hexa-his and c-Myc tag) was purified, refolded and used in the in vitro assay after analysis by SDS⁄ PAGE (see Supporting informa-tion, Fig S1B)
In vitro preprotein processing by SpsB The choice of the preprotein substrate was made after
a preliminary analysis of secreted proteins indicated in the genomic sequence data of S aureus The criteria for selection of the substrate were a good prediction of the presence and location of the signal peptide cleav-age site (as indicated by signalp 3.0 server [24]), and non-indication as a general protease The latter is not desirable because it could degrade the SPase itself Pre-IsaA was selected as the substrate for this assay IsaA was first identified as one of the four proteins expressed in vivo during sepsis caused by
Trang 3methicillin-resistant S aureus [25] It is a lytic transglycosylase
and was proposed to be important for the virulence of
S aureus along with another paralogue, SceD [26],
which is also a substrate of SpsB
The in vitro assay was carried out in the presence of
a protease inhibitor cocktail and the reactions were
stopped at different time intervals in the range 0–15 h
Analysis of the assay products by means of
immuno-detection of pre-IsaA⁄ IsaA revealed the presence of
two bands in the sample containing the preprotein
substrate and SpsB (Fig 1A) The upper band
corresponds to the unprocessed preprotein and the
lower one to the mature protein (predicted
MW = 22.5 kDa) As shown in Fig 1A, the substrate
remained unprocessed in the absence of the enzyme
The amount of preprotein processed increased over
time (Fig 1A) After 15 h, unprocessed protein
remained and the addition of fresh SpsB followed by
incubation for 3 h did not result in any significant
improvement in processing Similar observations of
incomplete processing have been made previously with
in vitro assays involving the SPases and preproteins
[21,27–29] and it has been suggested that the remaining
preprotein is probably in an unprocessible state
The addition of arylomycin A2 [15], a known SPase
inhibitor, to the reaction mixture containing the
enzyme and the substrate did not result in pre-IsaA
processing (Fig 1B) These observations confirmed the
in vitro activity of the purified SpsB The specificity of
the preprotein cleavage by SpsB was confirmed by
N-terminal sequence analysis of the mature protein
obtained The substrate was cleaved at the predicted
site (Fig 2), following the ()1, )3) or ‘Ala-X-Ala’ rule
[30] This substrate could also be processed by LepB,
the SPase of the Gram-negative bacterium E coli
under the same in vitro conditions described in the
present study (data not shown), indicating the broad substrate specificity of the SPases
A continuous fluorometric assay for SpsB and measurement of its specific enzymatic activity
A FRET-based assay was designed for SpsB The substrate used was an internally quenched peptide based on the sequence of the signal peptide region of Staphylococcus epidermidis SceD preprotein and containing 4-(4-dimethylaminophenylazo)benzoic acid⁄ 5-((2-aminoethyl)amino)-1-naphthalenesulfonic acid as the FRET pair SpsB was found to cleave this peptide efficiently in the presence of protease inhibitor cocktail,
to which the bacterial type I SPases are resistant (see Supporting information, Fig S2) The standardized assays were carried out in microtitre plates in a total volume of 100 lL in the assay buffer (50 mm Tris-HCl
pH 8; 0.5% Triton X-100) with a certain concentration
of SpsB (final concentration of 1 lm in most cases) and SceD peptide (final concentration of 5 or 10 lm,
as indicated) dissolved in dimethylformamide The final concentration of dimethylformamide in the reac-tion mixtures was 1% The hydrolysis of the peptide was measured by the increase in fluorescence on a
Fig 1 Preprotein processing by SpsB (full-length): (A) as function of time and (B) blocked by arylomycin A2 SpsB and pre-IsaA (at final con-centrations of 2 and 10 l M , respectively) were incubated at 37 C in the assay buffer for different time periods The proteins were separated
on 12.5% (w ⁄ v) SDS ⁄ PAA gels and analyzed by western blotting and chemiluminescent detection (A) Lane 1, SpsB (control); lane 2, pre-IsaA (control); lane 3, SpsB and pre-IsaA at time = 0; lanes 4–10, pre-IsaA processing by SpsB with increase in time; lane 11, pre-IsaA processing by SpsB after 900 min followed by addition of fresh SpsB (final concentration of 2 l M ) and further incubation for 3 h (B) SpsB and pre-IsaA (final concentrations of 1 and 10 l M , respectively) were incubated without and with arylomycin A2(final concentration of
200 l M ) for 15 h at 37 C Lane 1, pre-IsaA processing by SpsB; lane 2, pre-IsaA processing blocked by arylomycin A 2
Fig 2 SPase recognition sequence and cleavage sites of the SpsB substrates used in the present study: Showing part of the sequence
of the IsaA precursor (upper row) and the sequence of the SceD pep-tide (lower row) with the SPase cleavage sites indicated The SPase recognition sequence, which consists of small aliphatic residues at positions )1 and )3 relative to the cleavage sites, is shown in bold.
Trang 4microplate reader using excitation and emission
wave-lengths of 340 and 510 nm, respectively As part of the
validation of the assay, inhibitor arylomycin A2 was
used and no increase in fluorescence was observed in
the time-based scan (see Supporting information,
Fig S3A), confirming that the peptide remains
uncleaved when the enzyme activity is inhibited A
dose-dependent response to arylomycin A2was plotted
(see Supporting information, Fig S3B) and the IC50of
the inhibitor against SpsB was found to be 1 lm
(0.82 lgÆmL)1) The specificity of the proteolytic
reac-tion of the SceD peptide by SpsB was also analysed by
RP-HPLC to determine whether the SceD peptide was
cleaved at the expected cleavage site The resulting
fractions were subjected to ESI-MS and it was found
that the fluorogenic synthetic SceD peptide was
cleaved by S aureus SpsB at a single cleavage site and
that this cleavage occurred specifically at the predicted
site located at the A-S bond (data not shown) The
sequence and cleavage site of the SceD peptide are
shown in Fig 2
It should be noted that, at high substrate
concentra-tions (> 20 lm), the linear correlation between the
fluorescence and the substrate concentration is lost as
a result of the inner filter effect The inner filter effect
is the phenomenon observed when the fluorescent light
is absorbed by quenching groups on neighbouring
sub-strates or cleaved product molecules, allowing only a
fraction of light to be detected by the instrument
Therefore, only kcat⁄ Km could be measured using the
condition [S] << Km Consistent with this condition,
the time-course of the FRET assay with the enzyme
followed simple first-order kinetics (see Supporting
information, Fig S4) The pseudo-first-order rate
constant (Kobs) derived from these curves was directly
proportional to the enzyme concentration throughout
the experimentally accessible range of concentrations
(0.1–10 lm) The apparent second-order rate constant
kcat⁄ Kmor specific enzymatic activity of the full-length
SpsB was found to be 1.85 ± 0.13· 103m)1Æs)1 This
kcat⁄ Km value is approximately 26-fold higher than
that reported for E coli LepB in a continuous FRET
assay involving a fluorogenic synthetic peptide based
on maltose-binding protein [31]
Activity at varying pH and the pH-rate profile
of SpsB
The activity of SpsB over a range of pH was initially
determined by observing in vitro preprotein processing
in reaction buffers varying over the pH range 2–12
The enzyme was found to be active at the wide pH
range 5–12 but not at or below pH 4 (data not
shown) An assessment of the amount of preprotein processed at varying pH did not yield sufficient quanti-tative data, and therefore the FRET assay was used to study the effect of pH on the enzyme The stability of the synthetic SceD peptide substrate was determined
by incubating it in different buffers in the absence of the enzyme No increase in fluorescence was observed over the entire pH range 2–12 during the time-course
of the assay (data not shown), confirming its suitability for this purpose The enzyme reactions were carried out in different buffers over the pH range 2–12 and the increase in fluorescence was observed as a function
of time (see Supporting information, Fig S5) The curve obtained for pH 12 could not be fitted to obtain the exact kcat⁄ Km value (see Supporting information, Fig S5) However, the activity at pH 12 appears to be lower in terms of the initial velocity and, to plot the pH-rate profile, the approximate kcat⁄ Km value obtained was used The pH-rate profile obtained by plotting kcat⁄ Km versus pH was fitted with the equa-tion (Eqn 1) for a complex bell-shaped curve (Fig 3) Maximum activity for SpsB was observed at pH 7.9 ± 0.2 The high pH optimum of SpsB in vitro is consistent with those reported for the other SPases and is in agreement with the catalytic mechanism Spi (S pneumoniae), SipS (B subtilis) and LepB (E coli) have optima of pH 8, pH 10 and pH 9, respectively [21,28,32]
Fig 3 pH-rate profile of SpsB The calculated specific enzymatic activities (kcat⁄ K m ) obtained after carrying out the reactions in buffers varying over the pH range 4–12 were fitted using the equa-tion for a complex bell-shaped curve The results shown are the average of three independent experiments.
Trang 5kcat
Km
1
Hþ2
Ka3Ka2
þ kcat
Km
2
Hþ
Ka3
1þ HKþ a3þ HK þ2 a3Ka2þK Hþ3
a3Ka2Ka1
ð1Þ
The curve obtained from the pH-rate profile (Fig 3)
was not a typical single bell-shaped curve because there
appeared to be another smaller peak around pH 11 The
apparent pKa values for the free enzyme are
approxi-mately 6.6 and 8.7, with possibly another pKa around
11.8 The apparent pKavalue of 6.6 from the ascending
limb could correspond to lysine, which acts as a general
base in this class of enzyme It is interesting to note that
this value is 2.1 pH units lower than that observed for
LepB of E coli [32] and 4 pH units lower than the pKa
of lysine in solution The reason for the decreased pKa
of the active-site lysine in the SPases is not known It is
also unclear whether the hydrophobic environment of
the membrane contributes to this
The presence of two peaks in the pH-dependence
curve (Fig 3) and the high pKa1suggests that two acid
groups can play the role of acid catalyst, as represented
in Scheme 1 [33,34] Deprotonation of ESH2+ with a
pKa2of 8.7 decreases the rate of the catalyzed reaction
Further deprotonation of ESH+ with a pKa3 around
11.8 most likely stops the catalytic reaction (Scheme 1)
The kcat⁄ Kmvalues were calculated using Eqn (1)
For ESH2þ kcat
Km
ffi 1500 and ESHþ kcat
Km
ffi 400
Stability and the effect of temperature on the
in vitro activity of SpsB
As SPases are known to undergo degradation upon
incubation or storage over time, we tested the stability
of SpsB (full-length) by storing or incubating
the enzyme at 4, 27 or 37C for different lengths of
time in the presence of general protease inhibitors In
the sample stored at 4C for 9 days, only one band
corresponding to the native SpsB was observed
(Fig 4A) However, the kcat⁄ Km of this sample was
70 m)1Æs)1, which was 18.5-fold lower compared to the
enzyme stored at )80 C for the same length of time After 4 days of incubation at 27C, apart from the band corresponding to the native SpsB, a smaller protein was found (MW 18 kDa), which we desig-nated as sc-SpsB The amount of sc-SpsB increased over time and with increasing temperature The addition of arylomycin A2 blocked the appearance of sc-SpsB (Fig 4B), suggesting that this was a result of intermolecular self-cleavage
In vitro self-cleavage The N-terminal sequence analysis of the self-cleavage product sc-SpsB revealed that the enzyme was cleaved one amino acid before the catalytic serine (Fig 5) The self-cleavage site resembles the signal peptide cleavage site following the ()1, )3) rule for SPase recognition, as observed in the case of LepB, SipS and Spi A comparison of the site of cleavage
of SpsB with that of Spi from S pneumoniae shows that they are cleaved at the same point, whereas, in the case of SipS from B subtilis, the cleavage site is just after the catalytic serine (Fig 5) It has been reported that the self-cleavage products of Spi and SipS have no SPase activity [21,35] We tested the self-cleavage product sc-SpsB and also found it to be inactive at the concentration (1 lm) normally used for the FRET assay A very low residual activity was found when the concentration was increased (data not shown) These SPases (Spi, SipS and SpsB) have their self-cleavage site in the region around the catalytic serine, unlike in E coli LepB, where it is located in a hydrophilic domain connecting the two transmembrane domains at the N-terminus of the enzyme [36] The self-cleavage product of LepB was reported to have 100-fold less specific activity com-pared to the native enzyme [36] Although the above observations of cleavage were made in vitro, self-cleavage has also been reported to occur in vivo for Spi In the case of LepB, it is believed that the enzyme is protected from self-cleavage in vivo as a result of the autolysis site and the catalytic site being
at opposite sides of the membrane This view is sup-ported by studies involving membrane-incorporated LepB, where a dramatic decrease in self-cleavage was observed [37]
Expression, purification, in vitro activity and the requirement of detergent of an N-terminally truncated SpsB (tr-SpsB) derivative
Topology prediction for SpsB (see Experimental procedures) by tmhmm [38] and the porter server [39]
Scheme 1 Mechanism for two protonic states of the enzyme.
Trang 6indicated the presence of a single N-terminal
trans-membrane segment anchoring it to the trans-membrane The
tr-SpsB was designed to obtain a soluble derivative of
SpsB devoid of the transmembrane segment but
retain-ing the amino acids in the box B region (Fig 6) This
N-terminally hexa-his-tagged protein was found to be
in the soluble fraction when expressed in E coli and
could be purified under native conditions from the
cytoplasmic fraction by Ni2+-affinity chromatography
Further purification by cation exchange
chromato-graphy was required to obtain a pure sample suitable
for use in the in vitro assays (see Supporting
informa-tion, Fig S6) The tr-SpsB was able to process the
sub-strate pre-IsaA in vitro, confirming that the enzyme
activity was retained (see Supporting information,
Fig S7)
The specific activity of the truncated derivative was
determined using the FRET assay in the presence and
absence of detergents To achieve complete processing,
the final substrate concentration used for the truncated enzyme was 2.5 lm It was observed that the addition
of non-ionic Triton X-100 increased the activity of the enzyme, whereas the addition of sodium deoxycholate (ionic) or sulfobetain SB12 (zwitterionic) detergents rendered the enzyme inactive (data not shown) The apparent second-order rate constant kcat⁄ Km of the truncated enzyme was found to be 59.4 ± 6.4 m)1Æs)1 (Fig 7) in the presence of 0.5% Triton X-100 The specific activity was halved in the absence of detergents (data not shown) Three different concentrations of Triton X-100 were tested (0.1%, 0.5% and 1%) and it was found that the activity was maximum at 1%, although the difference between 0.5% and 1% was minor (data not shown) Detergent-dependent activity
of truncated SPase was first reported for E coli LepB [40] Among the Gram-positive bacteria,
detergent-Fig 5 Site of self-cleavage of SpsB in comparison with Spi and
SipS: alignment of SpsB with Spi and SipS sequences showing the
sites of self-cleavage The )1 and )3 positions relative to the
cleav-age sites are shown in bold, the catalytic serine is shown in italics
and the site of self-cleavage is indicated by an arrow.
Fig 6 N-terminal region of the SpsB sequence showing the differ-ence between tr-SpsB and sc-SpsB: The starting points of the trun-cated SpsB and the self-cleavage product of SpsB are inditrun-cated in the SpsB sequence The prediction of the transmembrane segment (TMS) was carried out using the PORTER server [39] The predicted TMS is shown in bold and the catalytic serine is shown in italics The conserved box B [6] is highlighted.
Fig 4 Stability of SpsB (A) at different temperatures and (B) in the presence of arylomycin A 2 (A) The stability of SpsB was tested by main-taining 20 lL aliquots of purified SpsB at different temperatures for up to 9 days The proteins were analyzed by SDS ⁄ PAGE followed by staining with CBB Lane 1, molecular weight marker; lane 2, SpsB stored at )80 C; lanes 3–5, SpsB incubated for 4, 6 and 9 days respec-tively at 4, 27 and 37 C, showing the full-length SpsB and the sc-SpsB (B) Purified full length SpsB was incubated without and with arylo-mycin A 2 (final concentration of 200 l M ) at 37 C for 7 days and analyzed by SDS ⁄ PAGE Lane 1, molecular weight marker; lane 2, SpsB without arylomycin A2(time = 0); lane 3, SpsB without arylomycin A2incubated for 7 days; SpsB with arylomycin A2(time = 0); lane 4, SpsB with arylomycin A2incubated for 7 days.
Trang 7dependent activity of the full-length SPase has been
reported in S pneumoniae, Spi [21], and in three of the
four SPases (SipX, SipY and SipZ) of S lividans [41]
In S lividans, a truncated SipY derivative devoid of
the C-terminal anchor was shown to be stimulated by
detergents, albeit to a lesser extent compared to the
full-length derivative [41] However, truncated SipS
from B subtilis was reported to have
detergent-inde-pendent activity [28] The effect of detergent on the
truncated SPase is most likely protein specific
Although it is not clear at this stage, the tr-SpsB
probably has a better conformation in the presence of
detergent, which could partially make up for the lack
of the hydrophobic membrane segment
Additionally, a truncated mutant in which the cata-lytic serine was replaced by alanine (data not shown) was used as a control in the FRET assay This mutant had a kcat⁄ Km value of 4 ± 0.8 m)1Æs)1, which is 14.8-fold lower than the active truncated or tr-SpsB and 462-fold lower than the full-length enzyme (Fig 7B) This also confirmed that the activity observed in the
in vitroassay is specifically a result of the enzyme SpsB and is not caused by background activity of LepB of
E coli (which was used as the host for overproduction
of SpsB)
The importance of the transmembrane segment for optimum activity of the SPases was also confirmed by these results, which revealed a 30-fold reduction in the specific activity of the tr-SpsB compared to the full-length enzyme A similar reduction in activity has been reported with truncated derivatives of LepB from
E coli and SipS from B subtilis and it was also shown that these enzymes maintain their high in vitro cleavage fidelity [42]
Interestingly, the observed activity of the truncated SpsB contrasts with that of sc-SpsB, the fragment obtained after self-cleavage, which was unable to cleave the substrate in the in vitro assay The tr-SpsB has nine additional amino acids at the N-terminus compared to sc-SpsB and three of these are part of the conserved box B region (Fig 6) In E coli LepB, the crystal structure [14] and modelling data [43] revealed that some of these corresponding amino acids are a part of the substrate binding pocket Furthermore, NMR experiments on the truncated derivative of LepB enzyme also showed that five of these amino acids are perturbed by substrate binding [17], highlighting their significance In SpsB, it is also likely that one or more
of the amino acids immediately preceding the catalytic serine form a part of the substrate-binding pocket They might also contribute to the correct folding and conformation of the enzyme
In conclusion, SpsB has certain common characteris-tics typical for SPases, which include a requirement for high pH and autocatalytic activity The transmem-brane segment and some of the amino acid residues preceding the catalytic serine are found to be impor-tant for optimum activity The FRET assay is suitable for high-throughput screening of compounds against SpsB, and the preprotein processing assay involving the physiologically relevant substrate pre-IsaA can serve as a confirmatory assay for identifying SpsB inhibitors We are currently testing compound libraries for potential inhibitors using these assays This line of research has the potential to result in a new class of
Fig 7 A comparison of the activities of the full-length and the
truncated SpsB derivatives (A) The enzyme assay was performed
using a final concentration of 5 l M (where [S] << K m ) of the
synthetic SceD peptide with the full-length (2 l M ), truncated (2 l M )
and an active site mutant (10 l M ) of SpsB in a reaction buffer at
37 C Fluorescent intensity was measured as a function of time
using Infinite M200 (B) The specific enzymatic activity k cat ⁄ K m of
the full-length and the truncated SpsB were compared using
varying concentrations of enzymes and a fixed concentration of the
peptide substrate (5 l M for the full-length and 2.5 l M for the
truncated) The pseudo-first-order rate constant Kobswas plotted as
a function of enzyme concentration.
Trang 8antibiotics that will contribute to tackling the problem
of drug resistance in S aureus
Experimental procedures
Bacterial strains, growth conditions and plasmids
E colistrains TG1 [44] and BL21(DE3)pLysS [45], used for
genetic manipulations and protein expression, respectively,
were grown at 37C in LB medium, supplemented with
ampicillin (50 lgÆmL)1) or chloramphenicol (25 lgÆmL)1),
where applicable The plasmids used are listed in Table 1
General molecular genetic techniques
DNA manipulations in E coli were carried out as described
previously [44] Plasmid DNA isolation, gel electrophoresis
and PCR clean-up were carried out using commercial kits
(Promega, Madison, WI, USA) according to the manufac-turer’s instructions
Cloning of spsB (full-length and truncated) and isaA
The gene encoding SpsB was amplified by PCR from
S aureus ATCC 65388 genomic DNA as template using the oligonucleotides fl-SpsB5 and fl-SpsB3 for the full-length and oligonucleotides tr-SpsB5 and fl-SpsB3 for the truncated derivative, respectively The oligonucleotides were designed based on the spsB gene sequence (source: http:// cmr.jcvi.org/tigr-scripts/CMR/CmrHomePage.cgi) The oli-gonucleotide sequences are provided in Table 2 and, as indicated, a hexa-histidine encoding sequence was included
at the 5¢ end The resulting PCR-amplified DNA fragments were first cloned in pGEM-T Easy (Promega) and subse-quently cloned as NdeI⁄ EcoRI fragments into pET-3a (Novagen, Madison, WI, USA) expression plasmid, which was also cut with the same restriction enzymes
The gene isaA was amplified from S aureus genomic DNA using oligonucleotides pIsaA5 and IsaA3Myc (Table 2) The forward primer pIsaA5 contained a hexa-his-tidine-encoding sequence and the reverse primer IsaA3Myc contained a c-Myc-encoding sequence PCR amplified DNA was cloned in pGEM-T Easy and subsequently cloned as a NcoI⁄ EcoRI fragment into the corresponding sites of pET-23d (Novagen)
Expression and purification of full-length SpsB
Expression of the protein was carried out essentially as described previously [45] E coli BL21(DE3)pLysS cells harbouring pET-fl-SpsB were grown in 600 ml LB medium
at 37C until D600of 0.6 was reached Isopropyl thio-b-d-galactoside was then added (final concentration of 1 mm) Three hours later, the cells were pelleted by centrifugation (4000 g at 4C for 10 min)
For purification of full-length SpsB, the cells were resus-pended in 20 mL of 50 mm Tris-HCl, pH 8, containing 20% sucrose and lysed by three passages through a French pressure cell at 15 000 psi After removal of the cell debris
by centrifugation (12 000 g at 4C for 10 min), the cell lysate was subjected to ultracentrifugation at 100 000 g for
Table 1 Plasmids used in the present study.
pGEM-T Easy 3¢-T overhang suited for cloning
PCR products; lacZ; Ampicillin
resistance (bla)
Promega
pET-3a T7 promoter; MCS; Ampicillin
resistance (bla)
Novagen pET-23d T7 promoter; MCS; Ampicillin
resistance (bla)
Novagen pET-fl-SpsB pET-3a derivative containing
hexa-his-encoding sequence
(5¢ end) and spsB between
NdeI and EcoRI
Present study
pET-tr-SpsB pET-3a derivative containing
hexa-his-encoding sequence
and 5¢ end truncated spsB
between NdeI and EcoRI
Present study
pET-pIsaA pET-23d derivative containing
hexa-his- (5¢ end) and
c-Myc-(3¢ end) encoding sequence
with pre-IsaA (immunodominant
staphylococcal antigen A precursor)
gene between NcoI and EcoRI.
Present study
Table 2 Oligonucleotides used in the present study Restriction sites are underlined, the hexa-histidine-encoding sequence is shown in italics and the c-myc-encoding sequence is shown in bold.
Trang 92 h The pellet was resuspended in 5 mL of buffer A
(50 mm NaH2PO4, 300 mm NaCl, pH 8.0) containing
10 mm imidazole and 0.5% of Triton X-100 The sample
was transferred onto a polypropylene column (Qiagen
GmbH, Hilden, Germany) loaded with Ni-NTA superflow
(IBA GmbH, Go¨ttingen Germany) and pre-equilibrated
with buffer A containing 10 mm imidazole The column
was placed on ice on a rotary shaker (45 r.p.m.) for 1 h
The column was washed twice with buffer A containing 10
and 20 mm imidazole, respectively, in the presence of
0.05% Triton X-100 Samples were eluted in two steps: first
with buffer A containing 100 mm imidazole and then with
buffer A containing 250 mm imidazole in the presence
of 0.05% Triton X-100 For analysis of purity, 4 lL of
6· SDS ⁄ PAGE loading buffer was added to 20 lL of
different elution fractions and incubated at 37C for
10 min followed by loading on 12.5% SDS⁄ PAGE gels
After separation of the proteins, the gel was stained with
Coomassie brilliant blue (CBB)
Expression and purification of the truncated
SpsB
For production of the truncated SpsB, E coli
BL21(DE3)-pLysS was transformed with the plasmid pET-tr-SpsB The
cell pellet obtained from 600 mL of culture of E coli
BL21(DE3)pLysS harbouring pET-tr-SpsB was resuspended
in 10 mL of buffer A with 10 mm imidazole and passed three
times through a French pressure cell at 15 000 psi After
cen-trifugation (12 000 g at 4C for 10 min), the clarified sample
was taken for purification by Ni2+-affinity chromatography
as described for the full-length SpsB The eluted fractions
were pooled and subjected to buffer exchange on PD-10
desalting column (GE Healthcare UK Limited, Chalfont
St Giles, UK) The sample eluted in 50 mm HEPES buffer,
pH 7.4, was further purified by cation exchange
chromatog-raphy using HiTrap SP FF column on AKTAprime plus
(GE Healthcare) in accordance with the manufacturer’s
instructions The fractions containing tr-SpsB were passed
through a PD-10 desalting column and eluted in 50 mm
Tris-HCl pH 8 The purified protein was observed on
CBB-stained SDS⁄ PAGE gel and subsequently used in the
in vitroassay
Expression and purification of pre-IsaA
Pre-IsaA (with a hexa-his-tag at the N-terminus and a
c-Myc tag at the C-terminus) was expressed in E coli
BL21(DE3)pLysS cells harbouring pET-pIsaA Isopropyl
thio-b-d-galactoside induction was carried out as described
above Additionally, sodium azide (final concentration
of 1 mm) was added to prevent the translocation of the
preprotein and subsequent cleavage of the signal peptide
Pre-IsaA was purified under denaturing conditions (8 m
urea) by Ni2+-affinity chromatography in accordance with
the manufacturer’s instructions (The QIAexpressionist; Qiagen, USA) Removal of urea and subsequent protein renaturation was carried out using PD10 columns The sample was eluted from the column in buffer containing
50 mm Tris-HCl pH 8 and 0.5% Triton X-100 The purified protein was then analyzed by SDS⁄ PAGE followed by western blotting
In vitro activity assay for SpsB using the preprotein pre-IsaA
The concentrations of the purified proteins were determined
by a Bio-Rad protein assay (Bio-Rad Laboratories GmbH, Mu¨nchen, Germany) based on the method of Bradford The enzyme SpsB (pre-treated with a protease inhibitor cocktail tablet; complete Mini, EDTA-free; Roche Diagnostics GmbH, Mannheim, Germany) and pre-IsaA were added to assay buffer (50 mm Tris-HCl, pH 8, with 0.5% Triton X-100) to achieve final concentrations of 2 lm and 10 lm, respectively, in a total volume of 20 lL and incubated at
37C for different periods of time in the range 0–15 h For the preprotein assay in the presence of inhibitor, arylomycin
A2(final concentration of 200 lm) was added to a reaction mixture containing SpsB (final concentration of 1 lm) in the assay buffer and incubated for 5 min at 37C followed by the addition of pre-IsaA (10 lm) The reactions were stopped
by addition of 4 lL of 6· SDS ⁄ PAGE sample loading buf-fer The proteins were separated by SDS⁄ PAGE using 12.5% (w⁄ v) PAA resolving gels and subsequently trans-ferred to a nitrocellulose membrane (Macherey Nagel, Du¨ren, Germany) For western blotting, anti-cMyc (DiaMed Benelux NV, Belgium) and anti-mouse IgG (whole-molecule)-alkaline phosphatase sera produced in rabbit (Sigma, St Louis, MO, USA) were used and chemi-lumeniscent detection was carried out using the Western StarTMkit (Tropix, Bedford, MA, USA) in accordance with the manufacturer’s instructions
Specificity of the cleavage of the SceD peptide
by SpsB
The synthesis and validation of the SceD peptide as a gen-eral SPase I substrate will be described elsewhere (K Bockstael, N Geukens, S Rao C.V., J Anne´, P Herd-ewijn, J Anne´ & A Van Aerschot, unpublished results) Additional SceD peptide for further work was obtained by custom peptide synthesis (Peptide Protein Research Ltd, Wickham, UK) The proteolysis of the peptide substrate was performed under conditions similar to those used to obtain previously reported experimental data [31] with some modifications (K Bockstael, N Geukens, S Rao C.V., J Anne´, P Herdewijn & A Van Aerschot, unpub-lished results) In brief, SpsB and SceD peptide (at final concentrations of 1 lm and 500 lm, respectively) were incu-bated at 37C for 15 h in a total reaction volume of
Trang 1040 lL A negative control reaction without SpsB was
included The reactions were stopped by the addition of
trifluoroacetic acid After centrifugation, supernatants from
the samples were applied to a RP-HPLC column The
resulting fractions were collected, lyophilized and
subse-quently subjected to ESI-MS analysis
FRET assay
The reaction mixtures contained SpsB (pretreated with
pro-tease inhibitor cocktail) and SceD peptide (dissolved in
dimethylformamide) at final concentrations of 1 and 10 lm,
respectively, in the assay buffer (50 mm Tris-HCl, pH 8,
with 0.5% Triton X-100) and the reactions were carried out
in 96-well (black, clear bottom) microtitre plates (Greiner
Bio One, Frickenhausen, Germany) at 37C in a total
volume of 100 lL The enzyme was initially pre-incubated
in the buffer for 5 min at 37C and the reaction was
started by the addition of the substrate Fluorescence
inten-sity measurements were taken as a function of time using
Infinite M200 automated microplate reader (Tecan
Austria GmbH, Gro¨dig, Austria) The excitation and
respectively The data obtained were fitted by nonlinear
curve fitting on Origin Pro 7.5 (OriginLab Corporation,
Northampton, MA, USA) using the equation y = [A0(1 –
e(–kt))] + B0, to achieve the first-order rate constant
k= Kobs The specific enzymatic activity was calculated
using the equation kcat⁄ Km= kobs⁄ [Enz]
The specific enzymatic activity or apparent second order
rate constant kcat⁄ Km of the full-length and the truncated
SpsB were measured with varying concentrations of the
enzymes (freshly purified) and a fixed concentration of the
peptide substrate, wherein [S] << Km(apparent) The final
concentration of the substrate was 5 lm for the full-length
and 2.5 lm for the truncated enzyme
FRET-assay with the inhibitor arylomycin A2
The inhibitor arylomycin A2 (Basilea Pharmaceutica Ltd.,
Basel, Switzerland) was dissolved in dimethylsulfoxide and
diluted to obtain different stock concentrations For the
in vitro assay, the reaction mixtures containing SpsB (final
concentration of 1 lm) with different concentrations of
arylomycin A2 were incubated in the assay buffer for
15 min The final concentration of dimethylsulfoxide in
each reaction mixture was 2% The fluorogenic synthetic
peptide SceD (5 or 10 lm) was added and fluorescence
intensity was measured as a function of time For
dose-dependent response and determination of IC50, ten different
concentrations of arylomycin A2 were used (two-fold
dilutions with a final concentration in the range 12.5–
0.0244 lm) and the substrate concentration was 10 lm
(final concentration) Percent inhibition was calculated
using the equation [(1 – (vi⁄ v0)]· 100, where viis the initial
velocity in the presence of inhibitor, v0is the initial velocity
in the absence of inhibitor but with (2%) dimethylsulfoxide The IC50 value was determined by fitting the percent inhibition versus inhibitor concentration using the Morgan– Mercer–Flodin model for a sigmoidal curve (Eqn 2)
y¼abþ cx
d
Activity at varying pH
For determination of optimum pH, the in vitro preprotein processing assay was carried out in buffers of varying pH: Glycine-HCl buffer, pH 2; citric acid⁄ sodium citrate buffer,
pH 3, 4 and 5; Clark and Lubs solutions: KH2PO4⁄ NaOH,
pH 6 and 7; Tris-HCl buffer, pH 7, 7.5, 8 and 8.5 and 9; glycine-NaOH buffer, pH 9 and 10; carbonate buffer, pH 10.9; phosphate buffer, pH 11; and hydroxide-chloride, pH
12, prepared as previously described [46]
The pH-rate profile using the synthetic SceD peptide was measured by calculating the kcat⁄ Kmvalues of the full-length enzyme incubated in buffers with varying pH It should be noted that the freshly purified enzyme was stored at 4C for approximately 24 h before use in the reactions The reactions were carried out in a total volume of 100 lL with a final con-centration of the enzyme of 1 lm After a pre-incubation of this reaction mixture for 5 min at 37C, the peptide sub-strate was added at a final concentration of 5 lm ([S] << Km) This was followed by measurement of fluores-cence intensity as a function of time The specific activity obtained was plotted as a function of pH using Eqn (1)
Stability at different temperatures
Purified SpsB (pre-treated with a general protease inhibitor) was aliquoted into polypropylene microfuge tubes (20 lL in each) and allowed to stand at different temperatures (27, 37
or 4C) for a maximum of 9 days All samples were initially stored at)80 C and collected in the reverse order for incu-bation, meaning that ninth day samples were incubated first followed by the sixth and the fourth and, finally, the 0 h sample was removed just before preparing the samples for loading on gel For stability of SpsB in the presence of inhib-itor arylomycin A2, 18 lL of purified length SpsB (stock concentration of 31 lm) was incubated with 2 lL of arylo-mycin A2(stock concentration of 2 mm) or dimethylsulfox-ide (control) at 37C for 7 days To these samples, 4 lL of SDS⁄ PAGE sample buffer was added and incubated for
10 min at 37C The proteins were separated on 12.5% w ⁄ v SDS⁄ PAGE gels followed by staining with CBB
N-terminal sequencing
The proteins were separated by SDS⁄ PAGE using 12.5% SDS⁄ PAGE gels followed by electroblotting onto poly